Skip to content

Driving Biopharmaceutical Advancements of Plant-Derived Cannabinoid-Based Products

At the MaRS Discovery District Toronto

Who We Are

Avicanna is a Canadian commercial-stage biopharmaceutical company

Leading in cannabinoid research, development, and evidence-based products for the global consumer medical and pharmaceutical segments.

Corporate Overview

Global commercialization strategy with diversified & high margin income streams across 12+ countries.

Comprehensive commercial portfolio
Consumer, medical cannabis and cannabinoid supply chain

Multinational sales with international footprint
USA, Canada, Europe and LATAM

Revenue generation and scale up phase
3 consecutive Q-Q growth of minimum 30%

Proven scientific platform, including R&D, pre-clinical and clinical infrastructure in Canada

Cannabinoid drug development pipeline
30+ advanced commercial SKUs + pharmaceutical pipeline

World-renowned collaborations
with leading Canadian academic and clinical institutions

JLABS @ Toronto, Johnson & Johnson Innovation Centre
R&D headquarters in the MaRS Discovery District

Established and environmentally sustainable low-cost vertical integration in Colombia

Two Colombian majority-owned subsidiaries
cultivation footprint of 480,000 sq feet with industrial extraction capacity

World-renowned collaborations
with leading Canadian academic and clinical institutions

Organic and sustainable cultivation
ranked highest amongst global cannabis companies in a corporate sustainability assessment – issued by S&P Global in 2020

Our Portfolio

Avicanna’s scientific platform has resulted in 30+ commercial and proprietary formulations and products

Including cosmetics, medical cannabis, pharmaceuticals in addition to its raw material business unit across international markets

Commercial Stage
Medical Cannabis and Wellness Products

Commercial Stage
CBD Dermacosmetics Consumer Retail Products*

In Development and Registration Stage
Pharmaceutical Pipeline

Commercial Stage
Cannabinoid API & Seeds

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products

Established Research & Development Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence Based Product

R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District Drug development pipeline, including sustained release tablets, transdermal patches and nano participle formulations

30+

Commercial stage proprietary products

10+

Scientists

7+

Canadian Government research grants awarded since 2020

8+

Pending Patents

4+

Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators

World-Class Collaborations

R&D and Clinical Partnerships Over the Past 4 Years

World-Class Collaborations

R&D and clinical collaborations with world-class academic and medical institutes since 2016

Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.

MaRS Discovery
District

University Health
Network

Hospital of
Sick Children

University of
Guelph

JLABS @ Toronto

University of
Toronto

Sunnybrook Health
Science Centre

Clinical Development

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products

08.08.2021

Products & Pipeline

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products